Publication Name	World Journal of Transplantation
Manuscript ID	38575
Country	Italy

Received	2018-02-28 23:54
Peer-Review Started	2018-03-01 01:48
To Make the First Decision	2018-03-19 00:39
Return for Revision	2018-03-23 02:47
Revised	2018-04-17 12:27
Second Decision	2018-05-30 11:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-05-30 22:19
Articles in Press	2018-05-30 22:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-08-04 09:14
Publish the Manuscript Online	2018-08-09 08:05

ISSN	2220-3230 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Transplantation
Manuscript Type	Review
Article Title	Hepatitis C and renal transplantation in era of new antiviral agents
Manuscript Source	Invited Manuscript
All Author List	Maurizio Salvadori and Aris Tsalouchos
Funding Agency and Grant Number
Corresponding Author	Maurizio Salvadori, MD, Professor, Department of Transplantation Renal Unit, Careggi University Hospital, viale Pieraccini 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Key Words	Hepatitis C virus; Renal transplantation; Hepatitis C virus and renal diseases; Interferon based therapies; Direct antiviral agents; Hepatitis C virus-positive donors
Core Tip	The prevalence of hepatitis C virus (HCV) infection is high in patients with end-stage renal disease and HCV has clinical challenges in patients who undergo kidney transplantation. Historically, interferon-based treatment options have been limited by low rates of efficacy and significant side effects, including risk of precipitating rejection. Direct acting antiviral (DAA) drugs revolutionized the treatment of HCV. In this review we highlighted the most recent studies and clinical trial with DAA in renal patients including patients waiting for transplantation and already transplanted. In these studies all-oral DAA therapy appears to be safe and effective for such patients.
Publish Date	2018-08-09 08:05
Citation	Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96
URL	http://www.wjgnet.com/2220-3230/full/v8/i4/84.htm
DOI	http://dx.doi.org/10.5500/wjt.v8.i4.84

Full Article (PDF)	WJT-8-84.pdf
Full Article (Word)	WJT-8-84.doc
Manuscript File	38575-Review.docx
Answering Reviewers	38575-Answering reviewers.pdf
Audio Core Tip	38575-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	38575-Conflict-of-interest statement.pdf
Copyright License Agreement	38575-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	38575-Approved-Grant-Application-Form(s)-or-Funding-Agency-Copy-of-any-Approval-Document(s)-revision.docx
Non-Native Speakers of English Editing Certificate	38575-Language certificate.pdf
Peer-review Report	38575-Peer-review(s).pdf
Scientific Misconduct Check	38575-Scientific misconduct check.pdf
Scientific Editor Work List	38575-Scientific editor work list.pdf